| 书目名称 | Combination Therapy In Dyslipidemia | | 编辑 | Maciej Banach | | 视频video | | | 概述 | Addresses a gap left by the latest dyslipidemia management guidelines.Current and comprehensive discussion of options for combination therapy of dyslipidemia.Contributions from an internationally accl | | 图书封面 |  | | 描述 | .Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. .Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia..Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtil | | 出版日期 | Book 2015 | | 关键词 | Alirocumab; Anacetrapib; Apolipoprotein B-100 inhibitors; Bile acid sequestrants; Bococizumab; CETP inhib | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-319-20433-8 | | isbn_softcover | 978-3-319-36721-7 | | isbn_ebook | 978-3-319-20433-8 | | copyright | Springer International Publishing Switzerland 2015 |
The information of publication is updating
|
|
发表于 2025-3-21 18:56:00
